KEY BENEFITS AND USES
- Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
- Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
- Identify untapped treatment scenarios and key competitors to aid trial design.
- Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
- Discover untapped populations to expand product share and drive strategic decisions.
- Where is my product positioned versus competitors’ products in the treatment journey?
- What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
- What are the market-relevant treatment scenarios, according to oncology experts?
- Where are the untapped business opportunities on which I can capitalize on?
- How can I optimize trial design and ensure a competitive edge for my pipeline asset?
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians.
PRIMARY MARKET RESEARCH
Survey of ~100 U.S. medical oncologists or urologists
- Bladder Cancer - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)
- Treatment Sequencing Bladder Cancer US May 2021
Author(s): Pragati Tripathi
Pragati Tripathi, M.Pharm., is an associate analyst on the Oncology team at DRG, part of Clarivate. Prior to joining DRG, she was a senior research associate in the intellectual property and research division at Evalueserve in Gurgaon. She conducted secondary research and delivered technology landscape reports in the domain of pharmaceutical sciences and healthcare. She obtained her master’s degree in pharmaceutical chemistry from the Birla Institute of Technology and Science in Pilani.